Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction: Potential Effect Modification by Abdominal Obesity. Insight from the Emphasis-Hf Trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: An excessive production of aldosterone influences outcome in patients with heart failure (HF) and in obese patients. Findings from laboratory studies suggest that chronic aldosterone blockade maybe more beneficial in abdominally obese HF-prone rats. In the current study, we investigated if the clinical response to a mineralocorticoid receptor antagonist in mildly symptomatic HF patients varied by abdominal obesity. Methods and results: A total of 2587 NYHA class II, reduced ejection fraction HF (HFrEF) patients enrolled in the EMPHASIS-HF trial were randomly assigned to eplerenone and placebo. In this post hoc analysis, patients were categorized according to waist circumference (WC) (normal if WC < 102 cm in men and < 88 cm in women; abdominal obesity if WC ≥ 102 cm in men and ≥ 88 cm women). The potential statistical interaction between the treatment and WC was assessed on the primary endpoint of death from cardiovascular causes or hospitalization for HF and other secondary endpoints. Over a median follow-up of 21 months, a significant benefit of eplerenone for the primary outcome was noted in both normal [hazard ratio (HR) 0.77, 95% confidence interval (CI) 0.61–0.98, P = 0.03] and increased (HR 0.48, 95% CI 0.37–0.63, P < 0.0001) WC subgroups, but the latter patients appeared to receive greater benefit than patients with normal WC (P for interaction = 0.01). This suggests a significant quantitative (treatment effect varies in magnitude by subgroup, but is always in same direction) rather than a qualitative interaction (direction of the treatment effect varies by subgroup) between eplerenone and WC in the adjusted analysis. Mean doses of eplerenone, blood pressure and serum potassium changes and adverse events were similar between WC subgroups. Conclusion: In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity. The findings are potentially hypothesis generating and need to be replicated in other HFrEF populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationObesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Overview of Epidemiology and Contribution of Obesity to Cardiovascular Disease
Bastien, M., Poirier, P., Lemieux, I., & Després, J.-P. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.10.016 · Cited by 1,125
Guo, C., Ricchiuti, V., Lian, B. Q., Yao, T. M., Coutinho, P., Romero, J. R., Li, J., Williams, G. H., & Adler, G. K. (2008) · Circulation · doi:10.1161/circulationaha.107.748640 · Cited by 342
Pivotal role of the mineralocorticoid receptor in corticosteroid‐induced adipogenesis
Caprio, M., Fève, B., Claës, A., Viengchareun, S., Lombès, M., & Zennaro, M.-C. (2007) · The FASEB Journal · doi:10.1096/fj.06-7970com · Cited by 337
The obesity paradox, weight loss, and coronary disease
Lavie, C. J., Milani, R. V., Artham, S. M., Patel, D. A., & Ventura, H. O. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.06.006 · Cited by 237
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade
Kosmala, W., Przewlocka-Kosmala, M., Szczepanik-Osadnik, H., Mysiak, A., & Marwick, T. H. (2013) · Heart · doi:10.1136/heartjnl-2012-303329 · Cited by 104
Aldosterone: A cardiovascular risk factor?
Funder, J. W., & Reincke, M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.08.005 · Cited by 47
Cited by
Packer, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
The Impact of Obesity on the Cardiovascular System
Csige, I., Ujvárosy, D., Szabó, Z., Lőrincz, I., Paragh, G., Harangi, M., & Somodi, S. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3407306 · Cited by 500
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction
Cohen, J. B., Schrauben, S. J., Zhao, L., Basso, M. D., Cvijic, M. E., Li, Z., Yarde, M., Wang, Z., Bhattacharya, P. T., Chirinos, D. A., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.09.009 · Cited by 432
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 370
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Self-citationSegar, M. W., Patel, K. V., Ayers, C., Basit, M., Tang, W. H. W., Willett, D., Berry, J., Grodin, J. L., & Pandey, A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1621 · Cited by 304
Packer, M. (2018) · Circulation · doi:10.1161/circulationaha.117.032474 · Cited by 263
Tomasoni, D., Adamo, M., Lombardi, C. M., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12555 · Cited by 258
Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“This hypothesis might explain why the total EAT mass measured by magnetic resonance imaging poorly correlates with myocardial fibrosis in HFrEF while having strong correlations in HFpEF [110].”
Metadata
- Authors
- Olivier, A., Pitt, B., Girerd, N., Lamiral, Z., Machu, J.-L., McMurray, J. J. V., Swedberg, K., van Veldhuisen, D. J., Collier, T. J., Pocock, S. J., Rossignol, P., Zannad, F., & Pizard, A.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-16
- Volume
- 19
- Issue
- 9
- Pages
- 1186-1197
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2596545081
- Cited by
- 112
- References
- 8
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.